New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For CAT;IQNT;GRMN;JCP;JNJ;KRC;NKTR;STRA;VRTX;VNO;BMY;PBR;HES From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 >>
August 18, 2015
08:39 EDTHESHess Corp. upgraded to Buy from Hold at Argus
Subscribe for More Information
07:29 EDTPBREnerCom to hold a conference
The Oil & Gas Conference is being held in Denver, Colorado on August 16-20 with webcasted company presentations to begin on August 18 at 10:00 am; not all company presentations may be webcasted. Webcast Link
07:22 EDTBMYBristol-Myers combo data could push shares above $70, says JPMorgan
JPMorgan analyst Chris Schott says the risk/reward for shares of Bristol-Myers Squibb looks "very attractive" ahead of the World Conference on Lung Cancer, which begins September 6. Data at the conference supportive of an Opdivo/Yervoy combo would represent a clear catalyst for the shares, Schott tells investors in a research note. Bristol is "already extremely well-positioned" in the advanced non-small cell lung cancer market, and data suggesting that the company has addressed toxicity concerns with the combo could push the stock above $70, Schott argues. Bristol closed yesterday up 39c to $63.47. The analyst sees limited downside to stock even with disappointing results at the World Conference on Lung Cancer. He reiterates an Overweight rating on Bristol with a $75 price target.
06:26 EDTPBRPetrobras may pay $1.6B to settle U.S. corruption probe, Reuters reports
Petrobras may face record penalties of $1.6B or more to settle U.S. criminal and civil investigations into its role in a corruption scandal, Reuters reports, citing a person briefed by the company's legal advisors. The company may pay the largest penalties ever given by U.S. authorities in a corporate corruption investigation, the report says. Reference Link
August 17, 2015
18:48 EDTIQNTInteliquent raises FY15 revenue view to $240M-$250M from $220M-$230M
Subscribe for More Information
18:45 EDTIQNTInteliquent enters three-year agreement with T-Mobile for IP voice services
Inteliquent (IQNT) announced that it had entered into a three-year agreement with T-Mobile (TMUS), under which Inteliquent will provide a full suite of IP voice services to T-Mobile. The agreement provides that T-Mobile will generally use Inteliquent as its sole provider of voice interconnection services for all calls exchanged between T-Mobile and nearly all other voice providers in the United States (excluding certain traffic, including among other things, traffic that is exchanged with other providers over peering arrangements). The agreement also includes Inteliquent's "Infrastructure as a Solution" offering. This offering allows a customer to remove its time division multiplexing interconnection from its network and use IP/SIP interconnection for voice services. Inteliquent expects that the agreement will result in a significant increase in the volume of traffic carried on Inteliquent's network.
12:23 EDTJCPStocks with call strike movement; Netflix J.C. Penney
Netflix (NFLX) January 150 call option implied volatility increased 2% to 48, J.C. Penney (JCP) January 10 call option implied volatility increased 1% to 40 according to IVolatility.
10:24 EDTJCPAnalyst notes give J.C. Penney shares a boost
Subscribe for More Information
10:21 EDTJCPOptions with decreasing implied volatility
Subscribe for More Information
10:09 EDTJCPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:26 EDTJCPOn The Fly: Pre-market Movers
HIGHER: AVEO (AVEO), up 119.7% after announcing licensing agreement with Novartis (NVS)... OHR Pharmaceutical (OHRP), up 24.9% after Soros reports new stake in company in 13F filing... Kite Pharma (KITE), up 4.6% after saying patient death unrelated to KTE-C19... Tesla (TSLA), up 5.5% after price target raised to $465 from $280 at Morgan Stanley... Mobileye (MBLY), up 2.7% after price target raised to $80 from $71 at Morgan Stanley... J.C. Penney (JCP), up 1.5% after being initiated with a Buy at B. Riley and Piper Jaffray raised its price target to $17 from $15. DOWN AFTER EARNINGS: Estee Lauder (EL), down 2.1% after reporting quarterly results and giving guidance for first quarter and fiscal 2016. ALSO LOWER: KKR (KKR), down 3.3% after Samson enters restructuring deal and expects to file for bankruptcy within 30 days... Aquinox (AQXP), down 4.7% after Lloyd Mackenzie, vice president - Technical Operations and Planning, disclosed late Friday the sale of 35,887 shares worth over $670,000 in a sale related to the exercise of options.
08:43 EDTBMYBristol-Myers sells Ixempra to R-PHARM, terms not disclosed
R-PHARM announces the acquisition of Ixempra from Bristol-Myers Squibb. Ixempra received marketing approval from the FDA in 2007 and in 18 other markets globally. Ixempra is indicated as monotherapy or in combination with capecitabine for the treatment of metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine. With the acquisition, R-PHARM has launched its U.S. commercial operations, and it is now responsible for all activities surrounding Ixempra's manufacture, distribution, sales, and reimbursement. Financial terms were not disclosed.
07:51 EDTPBRPetrobras volatility flat as share price and oil trends lower
Petrobras August call option implied volatility is at 69, September is at 68, October is at 66; compared to its 52-week range of 42 to 131, suggesting non-directional price movement.
07:40 EDTCATUBS to hold a tour
Midwest Construction & Farm Tour travels throughout Illinois and Iowa on August 17-18.
07:17 EDTJCPJ.C. Penney initiated with a Buy at B. Riley
B. Riley initiated J.C. Penney with a Buy rating and $12.50 price target. The firm sees positive business trends, despite industry headwinds, and numerous opportunities for margin recovery.
07:04 EDTGRMNGarmin expands mutliyear navigation partnership with Honda
Subscribe for More Information
06:51 EDTJCPJ.C. Penney price target raised to $17 from $15 at Piper Jaffray
Subscribe for More Information
06:38 EDTGRMNApple Watch revenue leader in wearable category, Business Insider reports
Subscribe for More Information
06:22 EDTVRTXPiper's Tenthoff sees select biotech names outperforming in second half
Piper Jaffray analyst Edward Tenthoff expects drug launches, clinical data read-outs and potential partnerships to drive outperformance for select biotech names in the second half of 2015. Despite some recent profit-taking, 2015 has been another strong year for biotech stocks, Tenthoff tells investors in a research note. Names with important second half of the year catalysts include Vertex (VRTX), Regeneron (REGN), Seattle Genetics (SGEN), Exelixis (EXEL), Sarepta (SRPT), Novavax (NVAX), Arrowhead (ARWR), Array BioPharma (ARRY), Alnylam (ALNY), Genocea (GNCA), CymaBay (CBAY), Idera Pharmaceuticals (IDRA), Vitae Pharmaceuticals (VTAE).
05:44 EDTJCPJ.C. Penney initiated with a Buy at B. Riley
B. Riley analyst Jeff Van Sinderen started shares of J.C. Penney with a Buy rating and $12.50 price target. The retailer closed Friday at $8.52. Sinderen views Penny as a "speculative turnaround" story and believes the company's "substantial" real estate assets partially offset its heavy debt load.
<< 1 | 2 | 3 | 4 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use